Clinical Trials

Inclusion Criteria:

• Able to understand all pertinent aspects of the study and has signed and dated a written informed consent form
• At least 18 years of age
• Able to speak, read, write, and comprehend US English fluently
• Has been diagnosed with Primary Myelofibrosis (PMF) or secondary Myelofibrosis (postessential thrombocythemia myelofibrosis [PET‐MF] and post‐polycythemia vera myelofibrosis [PPV‐MF]) as per World Health Organization (WHO) 2008 criteria
• Meets one of the following treatment criteria:
  • Failed prior treatment with a JAKi by investigator judgment (JAKi‐treated patients)
  • No prior JAKi treatment, and Intermediate‐1, Intermediate‐2 or High‐risk myelofibrosis according to the Dynamic International Prognostic Scoring System (DIPSS) (JAKi naïve patients)
• Has a palpable spleen
• Reports current symptoms that are common to MF (e.g., abdominal discomfort, bone or muscle pain, etc.); and
• Is willing and able to complete the study questionnaires and participate in a face‐to‐face or telephone interview session.

Exclusion Criteria:

• Prior treatment with a licensed or experimental smoothened inhibitor (SMOi)
• Targeted anti‐cancer therapy up to 14 days prior to enrolment (note prior treatment with best available therapy such as hydroxyurea is allowed)
• Has ruxolitinib discontinuation syndrome; and
• Subject has a
  • History of drug or alcohol abuse within the last 6 months,
  • Cognitive impairment,
  • Psychiatric condition or
  • Any other clinically relevant concern (e.g., impaired function due to current use of narcotics for pain treatment), that, in the opinion of the investigator, would interfere with the patient's ability to provide written informed consent and/or participate in the study procedures or interfere with the interpretation of the study results.